Intra-Cellular Therapies Inc. has identified phosphodiesterase PDE1 inhibitors reported to be useful for the treatment of cancer, Parkinson’s disease, cognitive disorders, narcolepsy, female sexual dysfunction, glaucoma, psychosis and traumatic brain injury, among other disorders.
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic (DA) neurons in the substantia nigra, leading to clinical symptoms such as tremors, rigidity, bradykinesia and postural instability.
Enveric Biosciences Inc. has released promising preclinical results for its lead neuroplastogen drug candidate, EB-003, in the open space forced swim test, a preclinical mouse model of severe depression and despair. In the first study, an oral dose of EB-003 at 30 mg/kg significantly reduced depression-like behavior within 30 minutes of administration.
University of Health Sciences and Pharmacy in St. Louis has described estrogen-related receptor α (ERR) modulators reported to be useful for the treatment of diabetes, amyotrophic lateral sclerosis, heart failure, breast cancer, renal disorders, metabolic diseases, Alzheimer’s disease and Parkinson’s disease, among others.
Otsuka Pharmaceutical Co. Ltd. has described macrophage colony-stimulating factor 1 receptor (CSF1R; CD115; c-Fms) inhibitors reported to be useful for diagnosis and treatment of pain, infections, amyotrophic lateral sclerosis, multiple sclerosis, cardiovascular disorders, Alzheimer’s disease and Parkinson’s disease, among others.
Researchers at North China Electric Power University and collaborators have developed novel radiolabels for the membrane-bound monoamine oxidase-B that feature a coumarin core.
Autism spectrum disorder, which affects around 1% of children worldwide, is as complex as the range of genetic and environmental factors that may contribute to it. Its complexity has made it difficult to identify effective treatments. Now researchers at Jazz Pharmaceuticals plc and Berand Neuropharmacology have demonstrated that a complex mixture extracted from Cannabis sativa shows therapeutic potential in one of the few preclinical models that mimics several characteristics of the disorder.
Aquinnah Pharmaceuticals Inc. has identified microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors reported to be useful for the treatment of Alzheimer's disease and frontotemporal dementia.
Vertex Pharmaceuticals Inc. has synthesized sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
RSS
